GALT · Galectin Therapeutics Inc

$3.85 -0.16 (-3.88%) At close · Jul 21

Market Cap

$253.22M

65.86M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-03-10	Virtual KOL Event	Event
2025-10-21	H.C. Wainwright Liver Disease Virtual Conference	Conference
2025-09-08	H.C. Wainwright 27th Annual Global Investment Conference	Conference
2025-06-16	Virtual KOL Event	Event
2025-01-23	Annual Meeting of Stockholders	Shareholder meeting
2024-10-07	H.C. Wainwright MASH Investment Conference	Conference
2024-09-09	H.C. Wainwright 26th Annual Global Investment Conference	Conference
2024-05-20	H.C. Wainwright BioConnect Investor Conference	Conference
2023-10-24	H.C. Wainwright 7th Annual NASH Investor Conference	Conference
2023-05-02	H.C. Wainwright BioConnect Investment Conference	Conference
2022-01-10	H.C. Wainwright BIOCONNECT Virtual Conference	Conference
2021-12-03	Annual Meeting of Stockholders	Shareholder meeting
2021-04-29	4th Global NASH Congress	Event
2021-03-09	H.C. Wainwright Global Life Sciences Conference	Conference
2020-12-17	4th Annual Digital NASH Summit	Event
2020-09-29	Galectin Therapeutics Investor Update Call	Event
2020-09-14	H.C. Wainwright 22nd Annual Global Investment Conference	Conference
2020-02-11	3rd Global NASH Congress 2020	Event
2019-12-04	Corporate Update	Event
2019-04-09	2019 H.C. Wainwright Global Life Sciences Conference	Conference
2018-09-06	H.C. Wainwright 20th Annual Global Investment Conference	Conference
2018-04-14	The International Liver CongressTM 2018, European Association for the Study of the Liver (EASL)	Event
2018-04-09	H.C. Wainwright Global Life Sciences Conference	Conference
2018-03-19	Bio Asia, Tokyo, Japan	Event
2018-03-19	2nd Annual H.C. Wainwright NASH Investor Conference. New York, NY	Conference

Source: https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-phase-2-nash-cirrhosis-clinical-trial

Key facts CIK 1133416 CUSIP 363225202 13F (30d) 7 filings 7 filers Visit website Investor relations